---
document_datetime: 2025-05-15 16:29:34
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/enspryng-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: enspryng-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.3713275
conversion_datetime: 2025-12-28 12:39:08.289222
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Enspryng

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10944 /202405  | Periodic Safety Update EU Single assessment - satralizumab (for centrally authorised products)                                                                   | 16/01/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| IB/0014              | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved | 27/09/2024                          |                                             | SmPC and Labelling               |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10944 /202311 | Periodic Safety Update EU Single assessment - satralizumab (for centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                     | 13/06/2024 | n/a | PRAC Recommendation - maintenance |
| PSUSA/10944 /202305 | Periodic Safety Update EU Single assessment - satralizumab (for centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                     | 11/01/2024 | n/a | PRAC Recommendation - maintenance |
| IB/0011/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 24/10/2023 | n/a |                                   |
| IB/0009             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                             | 08/08/2023 | n/a |                                   |
| PSUSA/10944 /202211 | Periodic Safety Update EU Single assessment - satralizumab (for centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                     | 06/07/2023 | n/a | PRAC Recommendation - maintenance |
| IB/0006             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                             | 20/04/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| N/0008              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                      | 17/03/2023 |            | PL                                |
| PSUSA/10944 /202205 | Periodic Safety Update EU Single assessment - satralizumab (for centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                        | 12/01/2023 | n/a        | PRAC Recommendation - maintenance |
| PSUSA/10944 /202111 | Periodic Safety Update EU Single assessment - satralizumab (for centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                        | 07/07/2022 | n/a        | PRAC Recommendation - maintenance |
| IB/0003/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 24/02/2022 | n/a        |                                   |
| IB/0002             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                  | 11/08/2021 | n/a        |                                   |
| IB/0001             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                   | 26/07/2021 | 30/06/2022 | SmPC, Labelling and               |